Trials / Completed
CompletedNCT05897190
Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster
Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine (RBMRNA-405) as a Booster in Chinese Adults & Older
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Argorna Pharmaceuticals Co., LTD · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study is to evaluate the safety and immunogenicity of a SARS-CoV-2 mRNA Vaccine as a heterologous booster dose in adults who completed 2 doses of inactivated vaccination through 12 months in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SARS-CoV-2 mRNA vaccine (RBMRNA-405) | Dose A |
| BIOLOGICAL | CoronaVac® | Dose B |
Timeline
- Start date
- 2022-05-16
- Primary completion
- 2022-06-13
- Completion
- 2023-05-12
- First posted
- 2023-06-09
- Last updated
- 2024-03-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05897190. Inclusion in this directory is not an endorsement.